No Data
Yabao Pharmaceutical Group Gets Registration Certificate for Oral Solution
Express News | Yabao pharmaceutical group: Subsidiary obtains the registration certificate for the oral solution of ambroxol.
yabao pharmaceutical group saw a year-on-year increase in revenue for two children's medications. Revenue for the injection of Benatuostin hydrochloride has not yet stopped declining. | Directly focusing on the earnings conference
At the earnings conference, yabao pharmaceutical group stated that in the first three quarters of this year, the company's pediatric products revenue increased year-on-year. The company's secretary of the board also mentioned that while the revenue of Tenatoprazole Hydrochloride Injection decreased, sales volume increased, and predicted that the 'income decline in this category will continue to narrow within the year'. yabao pharmaceutical group also provided explanations on the progress of the company's R&D pipeline, share buybacks, and other situations.
Express News | Yabao Pharmaceutical Group established a new biomedical company with 80 million yuan.
Yabao Pharmaceutical Group Co., Ltd. Report for the Third Quarter of 2024 (Revised Edition)
Yabao Pharmaceutical Group Co., Ltd. 2024 Third Quarter Report Correction Notice
No Data
No Data